BDTX (Black Diamond Therapeutics) Short Interest


BDTX Black Diamond Therapeutics Inc BDTX
38 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BDTX vs GUTS, ALPS, ONCY: Short Interest Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's Short Interest falls into.


BDTX
38GF Score
Black Diamond Therapeutics Inc BDTX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
38GF Score

Get the complete analysis for BDTX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price